<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age/><report-id>PHHY2012US113212</report-id><gender>unknown</gender><reactions><reaction>Acute tubular necrosis</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOLEDRONIC ACID</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053222_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134650</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012US113212</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-08</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-08</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012US113212</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Nelson</reportergivename>
			<reporterfamilyname>Leung</reporterfamilyname>
			<reporterorganization>Mayo Clinic</reporterorganization>
			<reporterdepartment>Division of Nephrology and Hypertension</reporterdepartment>
			<reporterstreet>200 1st NW Avenue,</reporterstreet>
			<reportercity>Rochester</reportercity>
			<reporterstate>MN</reporterstate>
			<reporterpostcode>55901</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Nelson L., Morie G.,Robert A. Kyle, Fernando C. Fervenza, Maria V. Irazabal,Alfonso E., et.al. Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy–Related Kidney Diseases. Clinical Journal of the American Society of Nephrology. 2012;7:1964-1968</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Multiple myeloma</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Acute tubular necrosis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Acute tubular necrosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal tubular necrosis</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOLEDRONIC ACID</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012US113212 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>literature report received on 08 Dec 2012: The authors discussed about, <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">Urinary </Semaphore><Semaphore x="1469401" class="Procedure" value="Albumin Measurement" score="1.00" ID="C64431">Albumin </Semaphore>Excretion (UAE) Patterns of Patients with Cast <Semaphore x="2294371" class="Disease or Finding" value="Nephropathy" score="1.00" ID="C34843">Nephropathy </Semaphore>(CN) and Other <Semaphore x="2237600" class="Disease or Finding" value="Monoclonal Gammopathy" score="1.00" ID="C35548">Monoclonal Gammopathy</Semaphore>–Related <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">Kidney </Semaphore>Diseases. This case refers to a patient of an unknown age and gender. The patient had medical history of <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">multiple myeloma</Semaphore>. The patient received <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.87" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown), for an unspecified indication, from an unknown date and at an unknown dose. On an unknown date, the patient had <Semaphore x="1426739" class="Disease or Finding" value="Acute Renal Failure with Tubular Necrosis" score="1.00" ID="C34749">acute tubular necrosis </Semaphore>(ATN) due to <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.87" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>. The seriousness, and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event were not reported. The causality of event was stated as suspected to <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.87" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>. The authors concluded that, this study showed that % UAE was significantly less in CN than the other three renal <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore>and % UAE may thus be helpful in <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>of CN.</narrativeincludeclinical>
				<sendercomment>MAC: Based on the available information, the causative role of the suspect product for the reported events cannot be entirely excluded.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>